The new breast cancer profile, the most significant test to date in Clarient's novel marker program, is the first product in Clarient's Insight Dx line of molecular tests. These tests are being commercialized to provide valuable cancer characterization information for prognosis and therapy selection for the major cancer types.
"This new agreement provides Clarient with an important addition to our breast cancer menu -- a new molecular diagnostic test that we believe predicts the likelihood of disease recurrence, and ultimately the benefit of chemotherapy for patients," said Clarient's President and CEO Ron Andrews. "Along with its significant value for the over 35,000 breast cancer patients we expect to test this year, Clarient's Insight Dx Breast Cancer Profile has the potential to deliver a significant economic opportunity for the company."
"We are excited to have entered into this agreement with Clarient," said Cornelius Diamond, Chief Executive Officer of Prediction Sciences. "The Clarient Insight Dx Breast Cancer Profile is the first in a pipeline of tests developed by Prediction Sciences that we believe will significantly improve and personalize patient care. We believe that Clarient is well positioned to commercialize this test and provide invaluable benefit to breast cancer patients and their physicians, allowing them to make informed treatment decisions."
Andrews added that the Clarient Insight Dx Breast Cancer Profile is the first of its kind to combine proteomic and genomic markers with tumor morphology data received directly from the patient's pathologist, thereby allowing a more accurate characterization of the disease.
"This clearly fits our business model of engaging and empowering the
community pathologist in the analysis process," Andrews said. "We believe
Copyright©2008 PR Newswire.
All rights reserved